Formic Acid

Formic Acid

SCHEMBL30584825

COc1ccc(-c2noc(N3CCN(C(=O)NCCCN4CCN(Cc5ccccn5)CC4)CC3)n2)cc1.O=CO

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.52
▸ MAPT P10636 5/20 0.52
▸ HTT P42858 4/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.52
▸ TP53 P04637 4/20 0.52
▸ KDM4E B2RXH2 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ GAA P10253 2/20 0.51
▸ NPC1 O15118 1/20 0.50
▸ POLB P06746 1/20 0.49
▸ HTR1A P08908 2/20 0.47
▸ HTR7 P34969 2/20 0.47
▸ TSHR P16473 3/20 0.47
▸ THRB P10828 1/20 0.45
▸ GSK3B P49841 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31667398 0.97 LMNA (0.55) LMNAMAPTHTTSMN1; SMN2TP53
Formic Acid SCHEMBL31546410 0.90 LMNA (0.56) LMNAMAPTHTTSMN1; SMN2TP53
Formic Acid SCHEMBL31546376 0.89 LMNA (0.49) LMNAMAPTHTTSMN1; SMN2TP53
SCHEMBL31667543 0.87 LMNA (0.58) LMNAMAPTHTTSMN1; SMN2TP53
SCHEMBL31667734 0.86 LMNA (0.51) LMNAMAPTHTTSMN1; SMN2TP53
SCHEMBL30584857 0.85 MAPT (0.57) LMNAMAPTHTTSMN1; SMN2TP53
Formic Acid SCHEMBL30584933 0.84 TSHR (0.65) LMNAMAPTHTTSMN1; SMN2TP53
Formic Acid SCHEMBL30584798 0.83 MEN1 (0.56) LMNAMAPTHTTSMN1; SMN2TP53
SCHEMBL30584958 0.83 MAPT (0.52) LMNAMAPTHTTSMN1; SMN2TP53
SCHEMBL31546418 0.79 LMNA (0.72) LMNAMAPTHTTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 — — EP disclosed
WO-2023177700-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2023-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 LMNA 1344/4885MAPT 2999/4885HTT 2290/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 LMNA 1344/4885MAPT 2999/4885HTT 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback